U.S. Markets closed

Endo Health announces availability 7.5mg, 15mg doses of crush-resistant Opana

Endo Health Solutions announced that its subsidiary, Endo Pharmaceuticals, has launched 7.5mg and 15mg strengths of its reformulated, designed to be crush-resistant, OPANA ER product. Now commercially available, the 7.5mg and 15mg options complete the launch of all approved strengths of the reformulated version of OPANA ER with INTAC technology. The product is now available in seven dosage strengths: 5, 7.5, 10, 15, 20, 30 and 40mg. With the launch of 7.5mg and 15mg OPANA ER designed to be crush-resistant, Endo filed a false advertising suit against Actavis calling for the company to cease and desist promoting its non-crush-resistant extended release oxymorphone HCl product as A-B rated, or bio-equivalent, to the reformulated OPANA ER. The lawsuit was filed earlier today.